David P. Salmon
Advances in cognitive science and cognitive neuroscience provide an opportunity to obtain new insights into Alzheimer’s disease (AD) and related disorders and to develop more effective ways to evaluate cognitive changes. Cognitive assessments are crucial for the diagnosis of neurocognitive disorders, for the evaluation of putative clinical trial effects, and for treatment planning. These assessments also provide an important basis for counseling of patients and families. The Cognition PIA aims to convene neuropsychologists, behavioral neurologists, and geriatric psychiatrists who are the world’s most prominent basic and clinical researchers on cognitive underpinnings of AD and related disorders to exchange information, discuss brain-cognition relationships, and establish an international consensus on cognitive “tools” for diagnostic assessment and treatment outcomes.